TY - JOUR
T1 - Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation
AU - Shinjoh, Masayoshi
AU - Miyairi, Isao
AU - Hoshino, Ken
AU - Takahashi, Takao
AU - Nakayama, Tetsuo
N1 - Funding Information:
This work was supported by Health Labour Sciences Research Grant, Japan, between 2003 and 2005, and the Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI(18790735), Grant-in-Aid for Young Scientists (B), Japan, between 2006 and 2008.
PY - 2008/12/9
Y1 - 2008/12/9
N2 - Immunizations using live-attenuated vaccines are not recommended for post-liver transplant children due to its theoretical risks. However, they will encounter vaccine-preventable viral diseases upon returning to real-life situations. We performed a total of 70 immunizations with four individual live-attenuated vaccines to 18 pediatric post-living donor liver transplant (LDLT) recipients who fulfilled a clinical criteria including humoral and cell-mediated immunity. The seroconversion rates at the first dose for measles (strain AIK-C), rubella (strain TO-336), varicella (strain Oka), and mumps (strains Hoshino) were 100% (15/15), 100% (15/15), 82% (9/11), and 82% (9/11), respectively. During observed period (-5 years 11 months), a few cases with waning immunity (antibodies were once produced but the levels fell over time) were seen except after rubella immunization. Clinical diseases after seroconversion or definite serious adverse effects due to immunization were not observed. Immunizations using selected live-attenuated vaccines were safe and effective for post-LDLT children who were not severely immunosuppressed.
AB - Immunizations using live-attenuated vaccines are not recommended for post-liver transplant children due to its theoretical risks. However, they will encounter vaccine-preventable viral diseases upon returning to real-life situations. We performed a total of 70 immunizations with four individual live-attenuated vaccines to 18 pediatric post-living donor liver transplant (LDLT) recipients who fulfilled a clinical criteria including humoral and cell-mediated immunity. The seroconversion rates at the first dose for measles (strain AIK-C), rubella (strain TO-336), varicella (strain Oka), and mumps (strains Hoshino) were 100% (15/15), 100% (15/15), 82% (9/11), and 82% (9/11), respectively. During observed period (-5 years 11 months), a few cases with waning immunity (antibodies were once produced but the levels fell over time) were seen except after rubella immunization. Clinical diseases after seroconversion or definite serious adverse effects due to immunization were not observed. Immunizations using selected live-attenuated vaccines were safe and effective for post-LDLT children who were not severely immunosuppressed.
KW - Children
KW - Immunization
KW - Live-attenuated
KW - Liver transplantation
UR - http://www.scopus.com/inward/record.url?scp=56649097352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649097352&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2008.09.076
DO - 10.1016/j.vaccine.2008.09.076
M3 - Article
C2 - 18930096
AN - SCOPUS:56649097352
SN - 0264-410X
VL - 26
SP - 6859
EP - 6863
JO - Vaccine
JF - Vaccine
IS - 52
ER -
